

RNAi

Technologies, Companies and Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

April 2018

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and US, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 476 publications include 30 books (6 as editor + 24 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

In 1998, Prof. Jain wrote a Textbook of Gene Therapy, which was the first book on this subject to be translated into the Chinese language in 2000. A book on gene therapy companies was published in 2000 by John Wiley & Sons and continued to be updated online at Wiley's web site until 2003 and is currently incorporated in the report on gene therapy published by Jain PharmaBiotech and is regularly updated with latest edition in 2015. Prof. Jain has edited "Drug Delivery Systems" (1st ed Humana/Springer 2008, 2nd ed 2014) and Drug Delivery to the Central Nervous System (Humana/Springer 2010). His other recent books include "Handbook of Nanomedicine" (Humana/Springer 2008; Chinese edition, Peking University Press 2011, 2nd ed Springer 2012, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2nd ed Springer 2017), "Handbook of Neuroprotection" (Springer 2011, 2nd edn 2018, in preparation), "Application of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Application of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer, 2014). He has edited "Applied Neurogenomics" (Springer 2015).

April 2018
Copyright © 2018 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: **+4161-6924461**
Email: **info@pharmabiotech.ch**
Web site: **http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	17
1. Technologies for suppressing gene function	19
Introduction	19
DNA transcription.....	19
RNA	19
<i>Non-coding RNA</i>	<i>19</i>
<i>RNA research and potential applications.....</i>	<i>21</i>
<i>Role of RNA in regulation of the dihydrofolate reductase gene</i>	<i>23</i>
Gene regulation	23
Post-transcriptional regulation of gene expression.....	24
Alternative RNA splicing.....	25
Technologies for gene suppression	25
Antisense oligonucleotides	25
Phosphorodiamidate morpholino oligomers.....	26
Transcription factor decoys	26
Aptamers.....	27
Ribozymes	27
Aptazymes.....	28
RNA aptamers vs allosteric ribozymes	28
Peptide nucleic acid.....	28
PNA-DNA chimeras.....	29
Locked nucleic acid	29
Long noncoding RNAs.....	29
Gene silencing	30
Post-transcriptional gene silencing	30
TargetTron™ technology for gene knockout.....	31
Definitions and terminology of RNAi	31
RNAi mechanisms	32
RNAi oligonucleotides	34
Non-promoter-associated small RNAs.....	34
Piwi-interacting RNAs in germ cell development	35
Relation of RNAi to junk DNA.....	35
RNAi and epigenetic mechanisms	36
RNA editing and RNAi	36
Historical landmarks in the development of RNAi	36
2. RNAi Technologies	39
Introduction	39
Comparison of antisense and RNAi	39
Advantages of antisense over siRNAs	39
Advantages of siRNAs over antisense	40
RNA aptamers vs siRNA	40
RNA Lassos versus siRNA.....	40
Concluding remarks on antisense vs RNAi	41
PMOs vs antisense and siRNAs	41
ssRNAi	41
Antisense vs DNP-ssRNA and DNP-siRNA	41
LNA and RNAi.....	42
LNA for gene suppression.....	42
Comparison of LNA and RNAi.....	43
Use of siLNA to improve siRNA.....	43
RNAi versus small molecules	43
RNAi in vivo	44
Cre-regulated RNAi in vivo	44
RNAi kits.....	44
ShortCut™ RNAi Kit.....	44
HiScribe™ RNAi Transcription Kit	45
pSUPER RNAi system.....	45
Si2 Silencing Duplex.....	46
Techniques for measuring RNAi-induced gene silencing	46
Application of PCR in RNAi.....	46
<i>Real-time quantitative PCR.....</i>	<i>47</i>
<i>Assessment of the silencing effect of siRNA by RT-PCR</i>	<i>47</i>
<i>Fluorescence resonance energy transfer probe for RNA interactions</i>	<i>48</i>
Bioinformatics tools for design of siRNAs	48
Random siRNA design.....	48

Rational siRNA design.....	49
<i>The concept of pooling siRNAs</i>	50
<i>Criteria for rational siRNA design</i>	50
<i>BLOCK-iT RNAi Designer</i>	50
<i>QIAGEN's 2-for-Silencing siRNA Duplexes</i>	51
<i>Designing vector-based siRNA</i>	51
<i>iRNAChek for designing siRNA</i>	51
<i>TROD: T7 RNAi Oligo Designer</i>	51
<i>siDirect: siRNA design software</i>	52
Prediction of efficacy of siRNAs	52
<i>Algorithms for prediction of siRNA efficacy</i>	52
<i>siRNA databases</i>	52
Production of siRNAs	53
Chemical synthesis of short oligonucleotides	53
In vitro transcription	53
Generation of siRNAs in vivo	54
UsiRNAs.....	54
siRNA:DNA hybrid molecules	55
Chemical modifications of siRNAs	55
<i>Sugar modifications of siRNA</i>	55
<i>Phosphate linkage modifications of siRNA</i>	55
<i>Modifications to the siRNA overhangs</i>	56
<i>Modifications to the duplex architecture</i>	56
<i>Applications of chemical modification of siRNAs</i>	56
Synthetic RNAs vs siRNAs	57
Specificity of siRNAs	57
Asymmetric interfering RNA	58
Genome-wide data sets for the production of esiRNAs	58
ddRNAi for inducing RNAi	58
ddRNAi technology	58
Advantages of ddRNAi over siRNA	59
Short hairpin RNAs	60
siRNA versus shRNA	60
Circular interfering RNA	61
Expressed interfering RNA	62
RNA-induced transcriptional silencing complex	62
Inhibition of gene expression by antigene RNA	63
RNAi vs mRNA modulation by small molecular weight compounds	63
saRNA for transcriptional activation	64
3. MicroRNA	65
Introduction	65
Circular RNA and miRNA	67
miRNA and RISC	67
Role of the microprocessor complex in miRNA	68
miRNAs compared to siRNAs	69
miRNA and stem cells	69
Influence of miRNA on stem cell formation and maintenance	69
Role of miRNAs in gene regulation during stem cell differentiation.....	70
miRNA databases	71
Sanger miRBase miRNA sequence database	71
Mapping miRNA genes	71
A database of ultraconserved sequences and miRNA function	72
A database for miRNA deregulation in human disease.....	72
An database of miRNA-target interactions	72
Role of miRNA in gene regulation	73
Control of gene expression by miRNA	73
<i>miRNA-mediated translational repression involving Piwi</i>	74
<i>Transcriptional regulators of ESCs control of miRNA gene expression</i>	74
Mechanism of miRNAs-induced silencing of gene expression.....	74
miRNA diagnostics	75
Biochemical approach to identification of miRNA	75
Computational approaches for the identification of miRNAs	75
LNA probes for exploring miRNA	75
miR-TRAP to identify miRNA targets in vivo.....	76
Microarrays for analysis of miRNA gene expression	76
<i>Microarrays vs quantitative PCR for measuring miRNAs</i>	77
miRNAs as biomarkers of hepatotoxicity	77
Modification of in situ hybridization for detection of miRNAs	78
Nuclease Protection Assay to measure miRNA expression.....	78
Real-time PCR for expression profiling of miRNAs.....	78

Significance of miRNAs in diagnostics	79
Targeting of miRNAs with antisense oligonucleotides	79
Silencing miRNAs by antagomirs	79
New tools for miRNA silencing	80
Use of HAPIScreen for identification of aptamers against pre-miRNAs	80
miRNA-regulated lentiviral vectors	80
miRNAs as drug targets	80
miRNAs as targets for antisense drugs	81
Challenges facing use of miRNAs as drug targets	81
Target specificity of miRNAs	82
Prediction of miRNA targets	82
Role of miRNA in human health and disease	83
Role of miRNAs in regulation of hematopoiesis	83
Role of miRNA depletion in tissue regeneration	84
Role of miRNA in regulation of aging	84
Role of miRNA in inflammation	84
Role of miRNAs in regulation of immune system	85
Role of miRNA in diabetes	85
Role of miRNA in the cardiovascular system	85
Role of miRNAs in development of the cardiovascular system	86
Role of miRNAs in angiogenesis	86
Role of miRNA in atherosclerosis	86
Role of miRNAs in cardiac hypertrophy and failure	86
Role of miRNA in cardiomyopathy	87
Role of miRNAs in conduction and rhythm disorders of the heart	88
Diagnostic and prognostic value of miRNAs in acute coronary syndrome	88
miRNA-based approaches for reduction of hypercholesterolemia	88
miRNA-based approach for restenosis following angioplasty	89
miRNA gene therapy for ischemic heart disease	89
miRNAs as therapeutic targets for cardiovascular diseases	90
Concluding remarks and future prospects of miRNA in the cardiovascular system	90
Role of miRNAs in diseases of the eye	90
Pathological ocular neovascularization	90
Role of miRNAs in diabetic retinopathy	91
Role of miRNAs in glaucoma	91
Role of miRNA in corneal scarring	91
Role of miRNAs in the nervous system	92
miRNAs and addiction	92
miRNAs in neurodegenerative disorders	93
<i>miRNAs as biomarkers of Alzheimer's disease</i>	94
<i>miRNAs in Parkinson disease</i>	95
<i>miRNAs in Huntington's disease</i>	95
<i>miRNAs in ALS</i>	96
<i>miRNAs as biomarkers of prion-induced neurodegeneration</i>	97
<i>miRNAs and retinal neurodegenerative disorders</i>	97
<i>miRNA and stroke</i>	97
<i>miRNA and schizophrenia</i>	98
Role of miRNA in neuroprotection	98
Role of miRNA in viral infections	99
Role of miRNA in HSV-1 latency	99
miRNA and autoimmune disorders	99
miRNA in rheumatoid arthritis	99
miRNA in systemic lupus erythematosus	100
miRNAs in gastrointestinal disorders	100
miRNA-based therapies for the irritable bowel syndrome	100
miRNA-based therapies for the inflammatory bowel disease	100
miRNA and skin disorders	101
Role of miRNA in inflammatory skin disorders	101
Role of miRNA in hypertrophic scarring of the skin	101
Role of miRNAs in cancer	101
miRNAs linked to the initiation and progression of cancer	102
Oncomirs	102
Linking miRNA sequences to cancer using RNA samples	103
Role of miRNAs in viral oncogenesis	103
miRNA genes in cancer	103
miRNAs interaction with p53	104
miRNAs, embryonic stem cells and cancer	105
miRNAs and cancer metastases	105
Role of miRNAs in cancer diagnosis	106
<i>Cancer miRNA signature</i>	106
<i>miRNA biomarkers in cancer</i>	106

<i>Diagnostic value of miRNA in cancer</i>	107
<i>Prognostic value of miRNA in cancer</i>	107
miRNA-based cancer therapeutics.....	107
<i>Antisense oligonucleotides targeted to miRNA</i>	108
<i>Role of miRNAs in adoptive immunotherapy of cancer</i>	108
<i>Restoration of tumor suppressor miRNAs to inhibit cancer</i>	108
<i>Delivery strategies for miRNA modulators in cancer</i>	109
Role of miRNAs in various cancers.....	110
<i>miRNA and brain tumors</i>	110
<i>miRNAs and CNS tumors in children</i>	112
<i>miRNAs and pituitary tumors</i>	113
<i>miRNA and breast cancer</i>	113
<i>miRNA and colorectal cancer</i>	114
<i>miRNA and gastrointestinal cancer</i>	114
<i>miRNA and leukemia</i>	115
<i>miRNA and lymphomas</i>	116
<i>miRNA and hepatocellular carcinoma</i>	116
<i>miRNA and lung cancer</i>	117
<i>miRNA and nasopharyngeal carcinoma</i>	118
<i>miRNA and ovarian cancer</i>	119
<i>miRNA and pancreatic cancer</i>	120
<i>miRNA and prostatic cancer</i>	120
<i>miRNA and thyroid cancer</i>	121
Companies involved in miRNA	121
Status of therapeutic development of miRNAs	122
Concluding remarks and future of miRNA therapeutics	123
4. Methods of delivery in RNAi	125
Introduction	125
Methods of delivery of oligonucleotides	125
Oral and rectal administration.....	126
Pulmonary administration.....	126
Targeted delivery to the CNS.....	127
<i>High flow microinfusion into the brain parenchyma</i>	127
Intracellular guidance by special techniques.....	127
Biochemical microinjection.....	128
Liposomes-mediated oligonucleotide delivery.....	128
Polyethylenimine-mediated oligonucleotide delivery.....	128
Delivery of TF Decoys.....	128
Biodegradable microparticles.....	129
<i>Microparticles</i>	129
<i>Nanoparticles</i>	129
Self-delivering rxRNA	130
siRNA delivery technologies	130
Local delivery of siRNA.....	131
In vivo delivery of siRNAs by synthetic vectors.....	131
Intracellular delivery of siRNAs.....	131
<i>Delivery of siRNAs with aptamer-siRNA chimeras</i>	132
<i>MPG-based delivery of siRNA</i>	133
<i>Protamine-antibody fusion proteins for delivery of siRNA to cells</i>	133
<i>Protein transduction domains</i>	133
<i>Phosphorothioate stimulated cellular delivery of siRNA</i>	134
Targeted delivery of siRNAs by lipid-based technologies.....	134
<i>Delivery of siRNA-lipoplexes</i>	134
<i>Lipidoids for delivery of siRNAs</i>	135
<i>NeoLipid™ technology</i>	135
<i>siFECTamine™</i>	135
<i>Systemic in vivo delivery of lipophilic siRNAs</i>	136
<i>Challenges and future prospects of lipid-based siRNA delivery</i>	136
Electroporation.....	136
<i>Nucleofactor technology</i>	137
<i>Visualization of electrotransfer of siRNA at single cell level</i>	137
Intravascular delivery of siRNA.....	137
27mer siRNA duplexes for improved delivery and potency.....	138
TransIT-TKO®.....	138
DNA-based plasmids for delivery of siRNA.....	139
<i>Convergent transcription</i>	140
PCR cassettes expressing siRNAs.....	140
Genetically engineered bacteria for delivery of shRNA.....	140
Viral vectors for delivery of siRNA.....	140
<i>Adenoviral vectors</i>	141

<i>Adeno-associated virus vectors for shRNA expression</i>	141
<i>Baculovirus vector</i>	141
<i>Lentiviral vectors</i>	142
<i>Retroviral delivery of siRNA</i>	143
Transkingdom RNAi delivery by genetically engineered bacteria	143
Delivery of siRNA without a vector	143
Cell-penetrating peptides for delivery of siRNAs	144
Role of nanobiotechnology in siRNA delivery	144
<i>Chitosan-coated nanoparticles for siRNA delivery</i>	144
<i>Cyclodextrin nanoparticles</i>	145
<i>Delivery of gold nanorod-siRNA nanoplex to dopaminergic neurons</i>	145
<i>Lipidic aminoglycoside as siRNA nanocarrier</i>	145
<i>Lipid nanoparticles-mediated siRNA delivery</i>	145
<i>Nanoparticles for intracellular delivery of siRNA</i>	146
<i>Nanosize liposomes for delivery of siRNA</i>	146
<i>PAMAM dendrimers for siRNA delivery</i>	147
<i>PEG-PCL-DEX polymersome-protamine vector</i>	147
<i>Polyethylenimine nanoparticles for siRNA delivery</i>	147
<i>Polycation-based nanoparticles for siRNA delivery</i>	148
<i>Quantum dots to monitor siRNA delivery</i>	148
<i>siRNA-nanoparticle conjugates for improving stability in serum</i>	149
<i>Systemic delivery of siRNAi by lipid nanoparticles</i>	149
<i>Topical delivery of siRNA-nanoparticle conjugates</i>	150
Targeted delivery of siRNAs to specific organs	150
<i>siRNA delivery to the CNS</i>	150
<i>siRNA delivery to the liver</i>	151
<i>siRNA delivery to the lungs</i>	152
Control of RNAi and siRNA levels	152
siRNA pharmacokinetics in mammalian cells	152
Mathematical modeling for determining the dosing schedule of siRNA.....	153
Assessing siRNA pharmacodynamics in animal models	153
Research on siRNA delivery funded by the NIH	154
Companies involved in delivery technologies for siRNA	154
5. RNAi in Research	157
Introduction	157
Basic RNAi research	157
<i>Antiviral role of RNAi in animal cells</i>	157
<i>Combination of siRNA with green fluorescent protein</i>	157
<i>Detection of cancer mutations</i>	158
<i>Genes and lifespan</i>	158
<i>Inducible and reversible RNAi</i>	158
<i>Loss-of-function genetic screens</i>	158
<i>Nanoparticles mimic RNAi</i>	159
<i>Profiling small RNAs</i>	159
<i>RNAi for research in neuroscience</i>	159
<i>RNAi and environmental research</i>	160
<i>Small nucleolar RNAs</i>	160
<i>Study of signaling pathways</i>	160
<i>Transgenic RNAi</i>	161
<i>Use of RNAi to study insulin action</i>	161
Applied RNAi research	161
RNAi for gene expression studies	161
Microarrays for measuring gene expression in RNAi.....	162
RNAi for functional genomic analysis	162
<i>RNAi studies on C. elegans</i>	163
<i>RNAi studies on Drosophila</i>	163
<i>RNAi in planaria</i>	164
RNAi for regenerative medicine.....	164
Testing the specificity of RNAi.....	165
Tissue-specific RNAi	165
siRNA-mediated gene silencing	165
RNAi libraries	165
<i>Enzymatic production of RNAi library</i>	166
<i>Next-generation libraries for RNAi-based genome-wide screens</i>	166
<i>pDual library using plasmid vector</i>	167
<i>pHippy plasmid vector library</i>	167
<i>siRNA libraries using pRetroSuper vector</i>	167
<i>siRNA produced by enzymatic engineering of DNA</i>	167
<i>shRNA libraries</i>	168
RNAi and alternative splicing	169

RNAi in animal development.....	169
<i>RNAi for creating transgenic animals</i>	169
<i>RNAi for creating models of neurological disorders</i>	170
Research support for RNAi in US.....	171
RNAi for toxicogenomics	171
Role of RNAi in the US biodefense research	171
The RNAi Consortium	171
Research support for RNAi in Europe.....	172
European Union for RNA Interference Technology	172
Research support of RNAi.....	173
Role of RNAi in MitoCheck project	173
RNAi Global Initiative	173
SIROCCO project.....	174
6. RNAi in drug discovery	177
Basis of RNAi for drug discovery	177
RIP-Chip for study of RNA-protein interactions.....	177
RNAi for identification of genes as therapeutic targets	178
Role of siRNAs in drug target identification	178
<i>Use of a genome-wide, siRNA library for drug discovery.....</i>	<i>179</i>
<i>Use of arrayed adenoviral siRNA libraries for drug discovery.....</i>	<i>179</i>
RNAi as a tool for assay development.....	179
Targeting human kinases with an siRNA library	179
Challenges of drug discovery with RNAi	180
Express Track SM siRNA Drug Discovery Program.....	180
Genome-wide siRNA screens in mammalian cells	181
<i>PhenomicIDTM.....</i>	<i>181</i>
Natural antisense and ncRNA as drug targets	181
RNAi for target validation.....	182
<i>Delivering siRNA for target validation in vivo</i>	<i>182</i>
<i>Validation of oncology targets discovered through RNAi screens.....</i>	<i>183</i>
<i>Selection of siRNA versus shRNA for target validation</i>	<i>184</i>
Off-target effects of siRNA-mediated gene silencing	184
<i>Bioinformatic approach to off-target effects.....</i>	<i>185</i>
<i>siPools for eliminating off-target effects of siRNAs.....</i>	<i>185</i>
<i>Managing off-target effects of vector-encoded shRNAs.....</i>	<i>185</i>
Application of RNAi to the druggable genome	186
Application of siRNA during preclinical drug development.....	186
siRNAs vs small molecules as drugs.....	187
siRNAs vs antisense drugs.....	187
Chemical modifications for improving siRNA drugs	187
RNAi technology in plants for drug discovery and development.....	188
<i>Application of RNAi to poppy plant as source of new drugs</i>	<i>188</i>
7. Therapeutic applications of RNAi	189
Introduction	189
Potential of RNAi-based therapies	190
In vitro applications of siRNA	190
In vivo applications of RNAi.....	191
RNAi and cell therapy	191
Gene inactivation to study hESCs.....	192
RNAi and stem cells	192
<i>RNAi for study of ESCs</i>	<i>193</i>
<i>RNAi and iPSCs.....</i>	<i>193</i>
Cell therapy for immune disorders	193
RNAi gene therapy.....	193
Drug-inducible systems for control of gene expression.....	194
Potential side effects of RNAi gene therapy.....	194
Systemic delivery of siRNAs	195
In vivo RNAi therapeutic efficacy in animal models of human diseases.....	195
Role of RNAi in regenerative medicine.....	196
Virus infections.....	197
RNAi approaches to viral infections.....	197
<i>Delivery of siRNAs in viral infections.....</i>	<i>198</i>
RNAi applications in HIV	198
<i>A multiple shRNA approach for silencing of HIV-1.....</i>	<i>199</i>
<i>Anti-HIV shRNA for AIDS lymphoma.....</i>	<i>199</i>
<i>Aptamer-mediated delivery of anti-HIV siRNAs</i>	<i>200</i>
<i>Bispecific siRNA constructs.....</i>	<i>200</i>
<i>Role of the nef gene during HIV-1 infection and RNAi</i>	<i>200</i>
<i>siRNA-directed inhibition of HIV-1 infection</i>	<i>201</i>

<i>Synergistic effect of snRNA and siRNA</i>	201
<i>Targeting CXCR4 with siRNAs</i>	202
<i>Targeting CCR5 with siRNAs</i>	202
<i>Concluding remarks on RNAi approach to HIV/AIDS</i>	202
Influenza	203
<i>Inhibition of influenza virus by siRNAs</i>	203
<i>Delivery of siRNA in influenza</i>	204
<i>Challenges and future prospects of siRNAs for influenza</i>	205
Respiratory syncytial and parainfluenza viruses	205
Coronavirus/severe acute respiratory syndrome	206
Herpes simplex virus 2	206
Hepatitis B	207
Hepatitis C virus	207
Cytomegalovirus	208
Virus causing hemorrhagic fever	209
<i>Dengue fever</i>	210
<i>Antivirals in development</i>	210
<i>Ebola virus</i>	211
<i>Marburg virus</i>	211
siRNA vs antisense oligonucleotides for viral infections	212
siRNA against methicillin-resistant <i>S. aureus</i>	212
RNAi-based rational approach to antimalarial drug discovery	212
Inhibiting the growth of malarial parasite by heme-binding DNA aptamers	213
siRNA-based antimalarial therapeutics	213
RNAi applications in oncology	213
Allele-specific inhibition	214
Drug delivery issues in managing cancer by RNAi approach	215
Inhibition of oncogenes	215
Modification of alternative splicing in cancer	217
Onconase	217
Overcoming drug resistance in cancer	217
<i>Targeting fusion proteins in cancer</i>	218
<i>Increasing chemosensitivity by RNAi</i>	218
RNAi approach to study TRAIL	219
RNAi-based logic circuit for identification of specific cancer cells	219
shRNA-based autologous cancer vaccine	219
siRNAs for anticancer drug discovery	220
siRNAs based on huntingtin trinucleotide repeats as anticancer reagents	221
siRNAs for inducing cancer immunity	221
siRNAs for inhibition of angiogenesis	221
siRNA targeting the R2 subunit of ribonucleotide reductase	222
siRNA for cancer chemoprevention	222
siHybrids vs siRNAs as anticancer agents	222
Nanobiotechnology-based delivery of siRNAs	223
<i>Lipid nanoparticle-based delivery of anticancer siRNAs</i>	223
<i>Minicells for targeted delivery of nanoscale anticancer therapeutics</i>	223
<i>Nanoimmunoliposome-based system for targeted delivery of siRNA</i>	224
<i>PEG-nanoparticles for delivery of siRNA to target fusion genes</i>	224
<i>Polymer nanoparticles for targeted delivery of anticancer siRNA</i>	225
<i>RNA nanotechnology for delivery of cancer therapeutics</i>	225
<i>siRNA delivery in combination with nanochemotherapy</i>	226
<i>Targeted delivery of a nanoparticle-siRNA complex in cancer patients</i>	226
Lipophilic siRNA for targeted delivery to solid tumors	226
RNAi-based treatment of various cancer types	227
<i>RNAi-based therapy of glioblastoma multiforme</i>	227
<i>RNAi in breast cancer</i>	229
<i>RNAi for enhancing hyperthermia/chemotherapy in cervical cancer</i>	229
<i>RNAi and colorectal cancer</i>	230
<i>RNAi and Ewing's sarcoma</i>	230
<i>RNAi and leukemias</i>	231
<i>RNAi and lung cancer</i>	231
<i>RNAi and melanoma</i>	231
<i>RNAi and pancreatic cancer</i>	232
<i>RNAi and prostate cancer</i>	233
Genetic disorders	233
RNAi for skin disorders	234
Experimental studies for RNAi applications in skin disorders	234
Clinical applications of RNAi in skin disorders	234
Pachyonychia congenita	235
Skin scarring	235
Neurological disorders	235

RNAi for neurodegenerative disorders.....	236
<i>Alzheimer's disease</i>	237
<i>Parkinson's disease</i>	237
<i>Amyotrophic lateral sclerosis</i>	238
<i>Prion diseases</i>	239
Polyglutamine-induced neurodegeneration	239
<i>Fragile X syndrome and RNAi</i>	240
<i>RNAi-based therapy for Huntington's disease</i>	240
Combination of RNAi and gene therapy to prevent neurodegenerative disease.....	242
Role of RNAi in pain therapy	242
Role of RNAi in repair of spinal cord injury	243
Role of RNAi in treatment of multiple sclerosis.....	243
siRNA for Duchenne muscular dystrophy	244
siRNA for dystonia.....	244
RNAi in ophthalmology	244
Age related macular degeneration.....	244
<i>Current treatment of AMD</i>	245
<i>RNAi-based treatments for AMD</i>	246
Diabetic retinopathy	247
Retinitis pigmentosa	248
RNAi and metabolic disorders	248
RNAi and obesity	248
<i>Genes and regulation of body fat</i>	248
RNAi and diabetes.....	248
<i>Regulation of insulin secretion by a miRNA</i>	249
<i>RNAi for study of genes in animal models of diabetes</i>	249
<i>RNAi for drug discovery in diabetes</i>	249
<i>RNAi for treating liver dysfunction in diabetes</i>	250
<i>siRNAs for study of glucose transporter</i>	251
<i>siRNAs for targeting adipose inflammation in diabetes and obesity</i>	251
RNAi in hematology	251
Stem cell-based gene therapy and RNAi for sickle cell disease	252
Targeting of antithrombin in hemophilia with RNAi	253
RNAi and disorders of the immune system	253
siRNA applications in immunology	253
Use of RNAi in transplantation	254
RNAi for cardiovascular disorders.....	255
RNAi for hypercholesterolemia.....	255
siRNAs targeting PCSK9	255
siRNA targeting NADPH oxidase in cardiovascular diseases.....	256
Role of lncRNA in cardiovascular disorders	257
siRNA for study and treatment of ischemia-reperfusion injury	257
RNAi in respiratory disorders.....	258
siRNA for cystic fibrosis	258
siRNA for asthma	258
RNAi for musculoskeletal disorders	258
RNAi for rheumatoid arthritis.....	258
RNAi for bone disorders	260
<i>RNAi for treatment of osteoporosis</i>	260
RNAi for miscellaneous disorders	260
<i>RNAi for transthyretin amyloidosis</i>	260
Research relevant to RNAi-based therapies at academic institutes	261
Laboratory of RNA Molecular Biology, The Rockefeller University	261
RNAi Center, La Jolla Institute for Allergy & Immunology	261
Clinical trials of RNAi-based therapies	262
Improving efficacy of siRNAs for clinical trials by improved delivery	263
Role of RNAi in development of personalized medicine.....	263
Future of RNAi	264
Challenges for the development of RNAi-based therapeutics.....	264
8. Safety, regulatory and patent issues	267
Introduction	267
Limitations and drawbacks of RNAi	267
Adverse effects of RNAi	267
Effect of siRNAs on interferon response	268
Detection of interferon response	268
Prevention of the interferon response in RNAi.....	269
Overcoming the innate immune response to siRNAs	269
Toxicity associated with RNAi	270
Selection of siRNAs to improve specificity and efficacy.....	270
Regulatory issues relevant to RNAi.....	270

RNAi patents	271
Companies with strong patent position	271
Alnylam	271
Benitec.....	274
Intradigm	274
Quark Pharmaceuticals	274
Sirna Therapeutics	275
9. Markets for RNAi Technologies	277
Introduction	277
Current and future market potential for RNAi technologies	277
RNAi reagents	278
siRNA markets.....	278
miRNA markets	278
RNAi-based drug discovery and target validation	278
RNAi-based development of therapeutics	278
RNAi market potential according to therapeutic areas.....	279
Market for viral infections	279
Market for cancer.....	280
Market for age related macular degeneration.....	280
Unmet needs in RNAi	280
Strategies for marketing RNAi	281
Choosing optimal indications	281
Strategies according to the trends in healthcare in the next decade	282
Concluding remarks	283
10. Companies involved in RNAi Technologies	285
Introduction	285
Major players in RNAi	289
Profiles of companies.....	289
Collaborations.....	479
11. References.....	487

Tables

Table 1-1: Various types of RNA	22
Table 1-2: Classification of small RNA molecules.....	31
Table 1-3: Mechanisms of small RNAs involved in gene silencing	33
Table 1-4: Historical landmarks in the evolution of RNAi	37
Table 2-1: RNAi versus small molecules.....	44
Table 2-2: Providers of software for siRNA design	49
Table 2-3: Methods for the production of siRNAs	53
Table 2-4: Advantages and limitations of methods of shRNA-derived siRNA knockdown	61
Table 2-5: Comparison of eiRNA with siRNA	62
Table 3-1: Methods for miRNA target prediction	82
Table 3-2: miRNA expression in neurodegenerative diseases.....	94
Table 3-3: Dysregulation of miRNA expression in epithelial cancers.....	102
Table 3-4: Delivery strategies for miRNA inhibition therapies in cancer	109
Table 3-5: Delivery strategies for miRNA replacement to inhibit cancer growth.....	109
Table 3-6: MiRNAs and key molecules in signaling pathways in glioblastoma multiforme.....	110
Table 3-7: Companies involved in miRNA diagnostics and therapeutics.....	121
Table 3-8: Status of therapeutic development of miRNAs.....	123
Table 4-1: Methods of delivery of oligonucleotides	125
Table 4-2: Methods of delivery of siRNA	130
Table 4-3: Companies developing siRNA delivery technologies.....	154
Table 5-1: RNAi libraries.....	166
Table 6-1: Delivery of siRNAs in vivo for target validation	182
Table 6-2: Selection of siRNA versus shRNA for target validation	184
Table 7-1: RNAi-based therapeutic approaches.....	190
Table 7-2: In vivo RNAi therapeutic efficacy in animal models of human diseases	195
Table 7-3: Inhibition of viral replication by RNAi	198
Table 7-4: Cancer-associated genes that can be targeted by RNAi	216
Table 7-5: Neurological disorders that have been studied by using RNAi	236
Table 7-6: Clinical trials of RNAi-based therapeutics.....	262
Table 9-1: RNAi markets according to technologies and reagents 2017-2027	277
Table 9-2: Markets for RNAi therapy for selected diseases: years 2017-2027	279
Table 10-1: RNAi reagent, technology and service companies	285
Table 10-2: Pharmaceutical companies using RNAi for drug discovery and development	286

Table 10-3: Biotechnology companies using RNAi for drug discovery and development.....	287
Table 10-4: Companies developing RNAi-based therapeutic products	288
Table 10-5: Major players in RNAi.....	289
Table 10-6: Proprietary reagents of ImuThes	364
Table 10-7: Product pipeline of Silence Therapeutics	448
Table 10-8: Collaborations in RNAi technologies	479

Figures

Figure 1-1: Relationship of DNA, RNA and protein in the cell	24
Figure 1-2: Schematic of suppression of gene expression by RNAi	32
Figure 1-3: Relation of RNAi to epigenetic mechanisms	36
Figure 2-1: Overview of ShortCut RNAi Kit.....	45
Figure 2-2: Gene silencing by RNAi induced with ddRNAi	59
Figure 2-3: saRNA for targeted gene activation	64
Figure 3-1: A schematic miRNA pathway with points of action of miRNA tools	65
Figure 3-2: Molecular mechanisms of miRNA generation.....	66
Figure 3-3: miRNA alternations in neurodegenerative diseases	93
Figure 4-1: RNA aptamer-mediated targeted RNAi delivery in cancer therapy.....	132
Figure 7-1: Targeting disease by RNAi.....	189
Figure 7-2: Mechanism of action of inclisiran	256
Figure 7-3: Role of RNAi in personalized medicine.....	263
Figure 8-1: Problems with use of synthetic siRNAs and measures to prevent them.....	268
Figure 9-1: Unmet needs in RNAi technologies	281